Education
About Us
Working with TipRanks
Follow Us
Evaxion Biotech (EVAX)
NASDAQ:EVAX
EVAX Stock Chart & Stats
$2.91
-$0.02(-2.40%)
At close: 4:00 PM EST
$2.91
-$0.02(-2.40%)
Day’s Range― - ―
52-Week Range$1.20 - $12.15
Previous CloseN/A
Volume99.85K
Average Volume (3M)68.46K
Market Cap
$19.77M
Enterprise Value$7.81M
Total Cash (Recent Filing)$10.57M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Apr 07, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding6,316,572
10 Day Avg. Volume92,515
30 Day Avg. Volume68,463
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-2.75
Price to Sales (P/S)1.36
P/FCF Ratio-0.35
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue1.02
Enterprise Value/Gross Profit1.02
Enterprise Value/Ebitda-1.31
Forecast
1Y Price Target
$12.33Price Target Upside323.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EvidenceProof-of-concept clinical data in melanoma showing durable benefit and sustained immune responses reinforces the vaccine's therapeutic potential and supports further development.
Strategic PartnershipsSecuring a strategic partnership or out-licensing deal for EVX-01 would validate the program, provide development resources, and signal commercial interest from a major pharmaceutical company.
Technology PlatformThe AI-driven immunology platform's ability to identify novel tumor neoantigens enhances the pipeline opportunity and increases attractiveness to potential collaborators.
Bears Say
Business Model RelianceA strategy that depends on partnering or out-licensing assets after early clinical proof-of-concept limits direct revenue upside and makes company value highly dependent on deal flow.
Manufacturing And ScalabilityPersonalized neoantigen vaccines face manufacturing and scalability constraints compared with conventional drug platforms, which could hinder commercial expansion.
Regulatory And IP RiskExposure to regulatory, clinical, intellectual property, and commercial challenges increases execution risk and could delay development or reduce the value of assets.
Evaxion Biotech News
EVAX FAQ
What was Evaxion Biotech’s price range in the past 12 months?
Evaxion Biotech lowest stock price was $1.20 and its highest was $12.15 in the past 12 months.
What is Evaxion Biotech’s market cap?
Evaxion Biotech’s market cap is $19.77M.
When is Evaxion Biotech’s upcoming earnings report date?
Evaxion Biotech’s upcoming earnings report date is Apr 07, 2026 which is in 59 days.
How were Evaxion Biotech’s earnings last quarter?
Evaxion Biotech released its earnings results on Nov 06, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.02.
Is Evaxion Biotech overvalued?
According to Wall Street analysts Evaxion Biotech’s price is currently Undervalued.
Does Evaxion Biotech pay dividends?
Evaxion Biotech does not currently pay dividends.
What is Evaxion Biotech’s EPS estimate?
Evaxion Biotech’s EPS estimate is -0.01.
How many shares outstanding does Evaxion Biotech have?
Evaxion Biotech has 6,316,572 shares outstanding.
What happened to Evaxion Biotech’s price movement after its last earnings report?
Evaxion Biotech reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 10.601%.
Which hedge fund is a major shareholder of Evaxion Biotech?
Currently, no hedge funds are holding shares in EVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evaxion Biotech
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
EVAX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and significant advancements in R&D, including a transformative deal with MSD and promising clinical data for EVX-01. However, market uncertainties and extended evaluation periods for deals, like EVX-B2, present challenges. Overall, the achievements and financial stability significantly outweigh the challenges.View all EVAX earnings summariesEVAX Stock 12 Month Forecast
Average Price Target
$12.33
▲(323.71% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.27% Other Institutional Investors
98.72% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---